A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy [metformin/pioglitazone] Compared to Pioglitazone HCl [pioglitazone] Monotherapy and to Metformin HCl [metformin] Monotherapy in the Treatment of Subjects With Type 2 Diabetes.

Trial Profile

A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy [metformin/pioglitazone] Compared to Pioglitazone HCl [pioglitazone] Monotherapy and to Metformin HCl [metformin] Monotherapy in the Treatment of Subjects With Type 2 Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Metformin/pioglitazone (Primary) ; Metformin; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Oct 2009 Results presented at the 20th World Diabetes Congress (WDC).
    • 01 Oct 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top